Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting

Vaccine

Volumn 27, Issue 34, 2009, Pages 4656-4661

  Jacobsen, Steven J ^a,b   Ackerson, Bradley K ^a,b   Sy, Lina S ^a,b   Tran, Trung N ^a,b   Jones, Tonia L ^a,b   Yao, Janis F ^a,b   Xie, Fagen ^a,b   Craig Cheetham, T ^a,b   Saddier, Patricia ^a,b  

^a KAISER PERMANENTE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Febrile convulsion; MMRV; Vaccination

Indexed keywords

CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; RUBELLA VACCINE; TYPHOID VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

ARTICLE; CHILD; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; FEBRILE CONVULSION; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; OBSERVATIONAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; VACCINATION REACTION;

CHICKENPOX VACCINE; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; INFANT; MALE; MANAGED CARE PROGRAMS; MEASLES-MUMPS-RUBELLA VACCINE; RETROSPECTIVE STUDIES; SEIZURES, FEBRILE; TIME FACTORS; UNITED STATES;

EID: 67649476079     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.056     Document Type: Article

References (17)

1. Luman E.T., Ching P.L., Jumaan A.O., and Seward J.F. Uptake of varicella vaccination among young children in the United States: a success story in eliminating racial and ethnic disparities. Pediatrics 117 (2006) 999-1008
2. Koslap-Petraco M.B., and Judelsohn R.G. Societal impact of combination vaccines: experiences of physicians, nurses, and parents. J Pediatr Health Care 22 (2008) 300-309
3. Shinefield H., Black S., Digilio L., Reisinger K., Blatter M., Gress J., et al. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J. 24 (2005) 665-669
4. Shinefield H., Williams W.R., Marchant C., Reisinger K., Stewart T., Meissner H.C., et al. Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J 24 (2005) 670-675
5. Kuter B.J., Hoffman Brown M.L., Hartzel J., Williams W.R., EvesiKaren A., Black S., et al. Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad). Hum Vaccine 2 (2006) 205-214
6. Lieberman J.M., Williams W.R., Miller J.M., Black S., Shinefield H., Henderson F., et al. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Pediatr Infect Dis J 25 (2006) 615-622
7. Reisinger K.S., Brown M.L., Xu J., Sullivan B.J., Marshall G.S., Nauert B., et al. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax. Pediatrics 117 (2006) 265-272
8. Bergstralh E.J., Kosanke J.L., and Jacobsen S.J. Software for optimal matching in observational studies. Epidemiology 73393 (1996) 331-332
9. Bonhoeffer J., Menkes J., Gold M.S., de Souza-Brito G., Fisher M.C., Halsey N., et al. Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine 22 (2004) 557-562
10. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19 (2000) 187-195
11. Black S., Shinefield H., Ray P., Lewis E., Hansen J., Schwalbe J., et al. Postmarketing evaluation of the safety and effectiveness of varicella vaccine. Pediatr Infect Dis J 18 (1999) 1041-1046
12. Barlow W.E., Davis R.L., Glasser J.W., Rhodes P.H., Thompson R.S., Mullooly J.P., et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med 345 (2001) 656-661
13. Virtanen M., Peltola H., Paunio M., and Heinonen O.P. Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. Pediatrics 106 (2000) E62
14. VARIVAX [Varicella Virus Live (Oka/Merck)]. Whitehouse Station (NJ): Merck & Co.; 2001.
15. ProQuad [Measles, Mumps, Rubella and Varicella (Oka/Merck) Virus Vaccine Live]. Whitehouse Station (NJ): Merck & Co.; 2005.
16. M-M-R II (Measles, Mumps, and Rubella Virus Vaccine Live). Whitehouse Station, NJ: Merck & Co.; 2004.
17. Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine. MMWR Morb Mortal Wkly Rep. 2008;57:258-60.